PD-1:PD-L1 blockade as host-directed therapy Anti-PD-1:PD-L1/2 therapy: improved efficacy with acceptable toxicity Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherap
anti-PD-1 antibody. These unique features of Met@Man-MPs contribute to boost anti-PD-1 antibody therapy, improving anticancer efficacy and long-term memory immunity after combination treatment. Our results support Met@Man-MPs as a potential drug to improve tumor resistance to anti-PD-1 therapy....
2023年11月02日,哥伦比亚大学爱尔文医学中心的研究人员在Cancer Cell期刊发表了题为:Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer的研究文章。与其他恶性肿瘤相比,原发性和去势抵抗性前列腺癌(CRPC)的肿瘤微环境(TME)...
Schematic of DOX@3D-MPs as an efficient enhancer for anti-PD-1 antibody therapy.aSchematic illustration of the preparation of DOX@3D-MPs.bSchematic illustration of DOX@3D-MPs to boost anti-PD-1 antibody therapy. DOX@3D-MPs efficiently targeted tumor cells and induced ICD of tumor cells to ...
PD-1/PD-L1 activity in the CRC microenvironment Monoclonal antibodies in CRC treatment Combination of PD-1 inhibitors and mAbs for cancer therapy Administration of inflammatory agents for CRC therapy Clinical trials and challenges Conclusions Funding Availability of data and materials Ethics approval and...
PD-1天然抗性(IPRES)的黑色素瘤存在一种特定的转录特征 根据IPRES定义了针对不同晚期癌症类型的转录组学分组 近日,来自美国加州大学洛杉矶分校的研究人员在国际学术期刊Cell上发表了一项最新研究进展,在这篇文章中他们利用组学的方法分析了转移性黑色素瘤病人在anti-PD-1免疫疗法治疗过程中的基因组学和转录组学特征。
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. First, increased PD-L1 level is an indicator of the pre-existed anti-tumor immune response which is positively correlated to response rate to anti-PD-1/PD-L1 treatment. Second, TIL is the effectors of anti-tumor immune response, ...
Flow cytometry was performed to detect the status of the immune microenvironment after CDK7 inhibition and antiPD-1 therapy in vivo. CD8 depletion antibodies were used to assess the role of CD8+ T cells in combined CDK7 and PD-1 blockade. The associations among CDK7, p38α, MYC, PD-L1,...
Successes with the anti-PD-1 antibodies pembrolizumab and nivolumab in the second-line treatment of advanced-stage non-small-cell lung cancer (NSCLC) have inevitably led to trials in the first-line setting. Results from three such trials were presented to packed crowds at the ESMO 2016 Congress...